Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.

Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans JM, Levallet G, Bordji K, Petit E, Branger P, Emery E, Manrique A, Barré L, Bernaudin M, Guillamo JS.

Eur J Nucl Med Mol Imaging. 2017 Mar 18. doi: 10.1007/s00259-017-3677-5. [Epub ahead of print]

PMID:
28315948
2.

Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, Capelle L, Delattre JY, Beauchesne P, Debouverie M, Fontaine D, Jouanneau E, Stecken J, Menei P, De Witte O, Colin P, Frappaz D, Lesimple T, Bauchet L, Lopes M, Bozec L, Moyal E, Deroulers C, Varlet P, Zanello M, Chretien F, Oppenheim C, Duffau H, Taillandier L, Pallud J;  for the Club de Neuro-Oncologie de la Société Française de Neurochirurgie and the Association des Neuro-Oncologues d'Expression Française..

J Neurosurg. 2017 Mar 3:1-11. doi: 10.3171/2016.10.JNS16710. [Epub ahead of print]

PMID:
28298039
3.

Pseudotumoral brain lesions: MRI review.

Renard D, Castelnovo G, Le Floch A, Guillamo JS, Thouvenot E.

Acta Neurol Belg. 2017 Mar;117(1):17-26. doi: 10.1007/s13760-016-0725-z. Epub 2016 Nov 22. Review.

PMID:
27878561
4.

Arrêt soudain des médicaments spécifiques de la démence au stade modéré à sévère de la maladie d'Alzheimer en institution : étude pilote longitudinale descriptive.

Saint-Paul LP, Martin J, Gaillard C, Garnier A, Mosquet B, Guillamo JS, Parienti JJ.

Therapie. 2015 Jul-Aug;70(4):313-9. doi: 10.2515/therapie/2014217. French.

PMID:
27393634
5.

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.

Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O, Anota A, Bonnetain F.

Cancer Med. 2016 Aug;5(8):1753-64. doi: 10.1002/cam4.734. Epub 2016 Jun 1.

6.

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A; POLA Network..

Neurology. 2015 Oct 13;85(15):1325-31. doi: 10.1212/WNL.0000000000002014. Epub 2015 Sep 18.

7.

[(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas.

Collet S, Valable S, Constans JM, Lechapt-Zalcman E, Roussel S, Delcroix N, Abbas A, Ibazizene M, Bernaudin M, Barré L, Derlon JM, Guillamo JS.

Neuroimage Clin. 2015 May 29;8:448-54. doi: 10.1016/j.nicl.2015.05.012. eCollection 2015.

8.

Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.

Ursu R, Taillibert S, Banissi C, Vicaut E, Bailon O, Le Rhun E, Guillamo JS, Psimaras D, Tibi A, Sacko A, Marantidou A, Belin C, Carpentier AF.

Cancer Sci. 2015 Sep;106(9):1212-8. doi: 10.1111/cas.12724. Epub 2015 Jul 29.

9.

[Sudden Discontinuation of Anti-dementia Drugs in Moderate and Severe Alzheimer's Disease in a Residency for Dependent Elderly People: a Longitudinal Descriptive Pilot Study].

Peyro Saint-Paul L, Martin J, Gaillard C, Garnier A, Mosquet B, Guillamo JS, Parienti JJ.

Therapie. 2015 Jul-Aug;70(4):313-9. doi: 10.2515/therapie/2014217. Epub 2015 Feb 16. French.

PMID:
25679184
10.

Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.

Pérès EA, Gérault AN, Valable S, Roussel S, Toutain J, Divoux D, Guillamo JS, Sanson M, Bernaudin M, Petit E.

Oncotarget. 2015 Feb 10;6(4):2101-19.

11.

IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.

Wang XW, Labussière M, Valable S, Pérès EA, Guillamo JS, Bernaudin M, Sanson M.

Biomed Res Int. 2014;2014:198697. doi: 10.1155/2014/198697. Epub 2014 May 7.

12.

Mobile phone use and brain tumours in the CERENAT case-control study.

Coureau G, Bouvier G, Lebailly P, Fabbro-Peray P, Gruber A, Leffondre K, Guillamo JS, Loiseau H, Mathoulin-Pélissier S, Salamon R, Baldi I.

Occup Environ Med. 2014 Jul;71(7):514-22. doi: 10.1136/oemed-2013-101754. Epub 2014 May 9.

PMID:
24816517
13.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O.

Ann Oncol. 2014 Jul;25(7):1442-7. doi: 10.1093/annonc/mdu148. Epub 2014 Apr 9.

PMID:
24723487
14.

Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.

Duntze J, Litré CF, Eap C, Théret E, Debreuve A, Jovenin N, Lechapt-Zalcman E, Metellus P, Colin P, Guillamo JS, Emery E, Menei P, Rousseaux P, Peruzzi P.

Ann Surg Oncol. 2013 Jun;20(6):2065-72. doi: 10.1245/s10434-012-2764-x. Epub 2012 Dec 2.

PMID:
23212763
15.

Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.

Corroyer-Dulmont A, Pérès EA, Petit E, Guillamo JS, Varoqueaux N, Roussel S, Toutain J, Divoux D, MacKenzie ET, Delamare J, Ibazizène M, Lecocq M, Jacobs AH, Barré L, Bernaudin M, Valable S.

Neuro Oncol. 2013 Jan;15(1):41-56. doi: 10.1093/neuonc/nos260. Epub 2012 Oct 31.

16.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

17.

[Anti-angiogenic strategies in glioblastoma].

Guillamo JS.

Rev Neurol (Paris). 2011 Oct;167(10):662-7. doi: 10.1016/j.neurol.2011.07.008. Epub 2011 Sep 1. Review. French.

PMID:
21889779
18.

Targeting the erythropoietin receptor on glioma cells reduces tumour growth.

Pérès EA, Valable S, Guillamo JS, Marteau L, Bernaudin JF, Roussel S, Lechapt-Zalcman E, Bernaudin M, Petit E.

Exp Cell Res. 2011 Oct 1;317(16):2321-32. doi: 10.1016/j.yexcr.2011.06.011. Epub 2011 Jun 30.

PMID:
21749867
19.

Five-Year Longitudinal MRI Follow-up and (1)H Single Voxel MRS in 14 patients with Gliomatosis Treated with Temodal, Radiotherapy and Antiangiogenic Therapy.

Constans JM, Collet S, Kauffmann F, Hossu G, Dou W, Ruan S, Rioult F, Derlon JM, Lechapt-Zalcmann E, Chapon F, Valable S, Théron J, Guillamo JS, Courthéoux P.

Neuroradiol J. 2011 Jun 30;24(3):401-14. Epub 2011 Jun 24.

PMID:
24059663
20.

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Gállego Pérez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour A, Cartalat-Carel S, Barrie M, Huchet A, Beauchesne P, Matta M, Mokhtari K, Tanguy ML, Honnorat J, Delattre JY.

J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27.

PMID:
21709196

Supplemental Content

Loading ...
Support Center